360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

SITAGLIPTIN

Image source: Freebase

Type: Product

Name: SITAGLIPTIN

First reported 8 hours ago - Updated 16 mins ago - 3 reports

Bristol, AstraZeneca Diabetes Drug Fails to Cut Heart Risk

--Onglyza had comparable cardiovascular safety to placebo in large trial--Results unlikely to give hoped-for lift to market for diabetes pills--Merck is conducting similar study of its blockbuster Januvia(Adds details and background throughout.)A diabetes ... [Published 4 Traders - 1 hour ago]

Entities: Onglyza, SITAGLIPTIN, Drugs, Diabetes

First reported Jun 17 2013 - Updated Jun 17 2013 - 1 reports

Drug Injury Law: Cancer of The Pancreas: Possible Side Effect For Diabetics Who Use Byetta, Januvia, Or Victoza?

Diabetes Doctors And Drug Safety Watchdog Group Express More Concern Than Ever Following June 2013 BMJ Medical Journal Article...By: Thomas J. Lamb ... [Published JD Supra - Jun 17 2013]

Entities: Byetta, SITAGLIPTIN, Victoza, Pancreas, Side Effect

First reported Jun 17 2013 - Updated Jun 17 2013 - 1 reports

READER POLL: Should Diabetes Drugmakers Provide Patient-Level Data?

Last week, the NIH ran a workshop to examine the safety of several widely used diabetes drugs and whether a definitive link can be established to acute pancreatitis and pancreatic cancer, which were the subject of recent studies that have generated ... [Published Pharmalot - Jun 17 2013]

Entities: Diabetes, Byetta, SITAGLIPTIN, pancreatitis

First reported Jun 17 2013 - Updated Jun 17 2013 - 2 reports

/C O R R E C T I O N -- Rheingold, Valet, Rheingold, McCartney & Giuffra LLP/

In the news release, Suit filed for Pancreatic Cancer By Use of Byetta, Januvia and Janumet, issued 17-Jun-2013 by Rheingold, Valet, Rheingold, McCartney & Giuffra LLP over PR Newswire, the source was originally transmitted incorrectly as Rheingold, Valet, ... [Published TickerTech.com - Jun 17 2013]

Entities: RHEINGOLD, JANUMET, Pancreatic Cancer, Byetta

First reported Jun 13 2013 - Updated Jun 14 2013 - 2 reports

SITAGLIPTIN

Rottenstein Law Group LLP Comments on Drugmakers' Cooperation With Safety Review of Byetta, Januvia, Victoza

This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.SOURCE:The firm is currently evaluating Byetta, Victoza and Januvia lawsuits for those who have suffered from ... [Published KXXV-TV - Jun 14 2013]

Entities: Byetta, SITAGLIPTIN, Victoza

First reported Jun 14 2013 - Updated Jun 14 2013 - 1 reports

FDA Food & Drug Administration

Diabetes Meds Face FDA Scrutiny for Pancreas Risks

Medscape Medical NewsBy Lisa Nainggolan More from WebMD Prediabetes Linked to Stroke RiskWaist Size Alone May Predict Diabetes RiskPeople With Diabetes May Need Earlier Colon ScreenMarch 14, 2013 -- The FDA is looking into an increased risk of pancreatitis ... [Published UPN 38 - Jun 14 2013]

Entities: FDA Food & Drug Administration, Pancreas, Diabetes, Byetta

First reported Jun 12 2013 - Updated Jun 13 2013 - 5 reports

Diabetes Drugs And Pancreatic Cancer: Drugmakers Will Cooperate In Safety Review

By Bill Berkrot NEW YORK, June 12 (Reuters) - Global drugmakers said on Wednesday they would cooperate with an independent review to address concerns of a potential link between widely used diabetes medicines and pancreatic cancer and other safety ... [Published The Huffington Post | Full News Feed - Jun 13 2013]

Entities: SITAGLIPTIN, Pancreatic Cancer, Diabetes

First reported Jun 13 2013 - Updated Jun 13 2013 - 1 reports

Merck Lauds Call for Safety Review of Incretin-Based Diabetes Drugs

Merck Welcomes Independent Review of the Safety Profile of Januvia (Sitagliptin) and Other Diabetes Medicines WHITEHOUSE STATION, N.J., June 12, 2013 --(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada,... ... [Published Drugs.com - Jun 13 2013]

Entities: Merck & Co Inc, Diabetes, SITAGLIPTIN, Drugs

First reported Jun 12 2013 - Updated Jun 13 2013 - 2 reports

Merck & Co., Inc. (MRK), Pfizer Inc. (PFE): Juicy Dividends From the Three Pharmaceutical Giants

Merck & Co., Inc. (NYSE: MRK ) has been trying to generate more value for its shareholders via its share buyback program. Recently, it has also had a repurchase agreement to buy back its shares held by Goldman Sachs, with a total transaction value of ... [Published InsiderMonkey.com - Jun 12 2013]

Entities: Merck & Co Inc, Pfizer Inc, New York Stock Exchange, Singulair, Patent

First reported Jun 12 2013 - Updated Jun 12 2013 - 1 reports

Pipeline vs. Expiring Patents: Eli Lilly’s Future

Notwithstanding management promulgations to the contrary, investors remain circumspect about Eli Lilly’s ( LLY ) ability to successfully navigate hurdles to earnings and cash flow growth following the loss of market protection of top-selling drugs in ... [Published YCharts - Jun 12 2013]

Entities: Eli Lilly & Company, YCharts Inc, Drugs, empagliflozin, FDA Food & Drug Administration

First reported Jun 12 2013 - Updated Jun 12 2013 - 10 reports

Signing a sweet deal

WHITEHOUSE STATION, N.J.While on the surface, it seems strange for two giant pharmaceutical companies to collaborate on anything, it appears that lately, many are doing just that in order to make an impact in the $35-billion global diabetes drug market. ... [Published Drug Discovery News - Jun 12 2013]

Entities: Merck & Co Inc, Pfizer Inc, DPP-4

First reported Jun 12 2013 - Updated Jun 12 2013 - 1 reports

12th Q&A With Dr. Bernstein

Dr. Richard K. BernsteinDr. Richard K. BernsteinCan Januvia Trigger Cancer Symptoms?I have been a type 2 diabetic for more than 10 years, and have been on Januvia for about half that time (previously Avandia). I recently read a Dr. Mercola piece where ... [Published Diabetes Health Magazine - Jun 12 2013]

Entities: SITAGLIPTIN, Richard K. Bernstein, Diabetes, Blood Glucose

Quotes

The study will be "viewed as more of a missed opportunity to boost Onglyza and the overall class" Bernstein analyst Tim Anderson said

Bristol, AstraZeneca Diabetes Drug Fails to Cut Heart Risk [Published 4 Traders - 1 hour ago]

"From our examination of the data, it appears to us that there has been over promotion and under warning by the sellers of these and other drugs in the incretin category" says Paul D Rheingold, senior partner in the law firm. The firm specializes in representing persons injured by drugs and medical devices...

/C O R R E C T I O N -- Rheingold, Valet, Rheingold, McCartney & Giuffra LLP/ [Published TickerTech.com - Jun 17 2013]

"MRL’s organizational structure has been altered to simplify governance so that Merck (MRK ) can advance therapeutic and vaccine candidates more efficiently and focus resources on its most promising programs. The new design has been established to ensure that MRL leaders have the authority to take appropriate actions to facilitate rapid pipeline progress. It is too early to provide numbers or comment on any individuals that may or may not be affected by these changes."

Can New Merck R&D Chief End Lost Decade? [Published YCharts - Jun 15 2013]

...week for the BritishBritish Medical Journal (BMJ) on the safety of incretin-based therapies, the journal's editor Dr Fiona Godlee commented that "instead of engaging in open debate about legitimate and important scientific questions, the manufacturers have been unwilling to share their data [and] patients and doctors have not been kept properly informed about the uncertainties surrounding these drugs."

US charity calls for release of diabetes drug data [Published PMLive - Jun 14 2013]

More Content

sort by: Date \| Relevance
Bristol, AstraZeneca Diabetes Drug Fails to Cut... [Published 4 Traders - 1 hour ago]
A Bristol-Myers And AstraZeneca Diabetes Trial ... [Published Pharmalot - 2 hours ago]
AstraZeneca, Bristol diabetes drug disappoints ... [Published Yahoo! News - 8 hours ago]
UPDATE 1-AstraZeneca, Bristol diabetes drug dis... [Published CNBC - 9 hours ago]
ADA/JDRF Type 1 Diabetes Sourcebook, Excerpt #4... [Published Diabetes in Control - Jun 17 2013]
/C O R R E C T I O N -- Rheingold, Valet, Rhein... [Published TickerTech.com - Jun 17 2013]
Drug Injury Law: Cancer of The Pancreas: Possib... [Published JD Supra - Jun 17 2013]
Suit filed for Pancreatic Cancer By Use of Byet... [Published FinanzNachrichten.de - Jun 17 2013]
Suit filed for Pancreatic Cancer By Use of Byet... [Published PR Newswire: Health - Jun 17 2013]
READER POLL: Should Diabetes Drugmakers Provide... [Published Pharmalot - Jun 17 2013]
Can New Merck R&D Chief End Lost Decade? [Published YCharts - Jun 15 2013]
Codexis climbs on Chemtex production milestone [Published CNBC - Jun 14 2013]
New Merck R&D Chief Overhauls Operations & Cuts... [Published Pharmalot - Jun 14 2013]
AstraZeneca and Bristol-Myers Squibb to Present... [Published OSIX News - Jun 14 2013]
US charity calls for release of diabetes drug data [Published PMLive - Jun 14 2013]
Rottenstein Law Group LLP Comments on Drugmaker... [Published KXXV-TV - Jun 14 2013]
Diabetes Meds Face FDA Scrutiny for Pancreas Risks [Published UPN 38 - Jun 14 2013]
Rottenstein Law Group LLP Comments on Drugmaker... [Published Street Insider - Jun 13 2013]
Diabetes Drugs And Pancreatic Cancer: Drugmaker... [Published The Huffington Post \| Full News Feed - Jun 13 2013]
Merck Lauds Call for Safety Review of Incretin-... [Published Drugs.com - Jun 13 2013]
Lexicon Pharmaceuticals' Management Presents at... [Published Seeking Alpha - Jun 13 2013]
Pipeline vs. Expiring Patents: Eli Lilly’s Future [Published YCharts - Jun 12 2013]
Signing a sweet deal [Published Drug Discovery News - Jun 12 2013]
Drugmakers to cooperate in safety review of dia... [Published Reuters - Jun 12 2013]
Cancer of The Pancreas: Possible Side Effect Fo... [Published Drug Injury Watch - Jun 12 2013]
Confab reviews safety of diabetes drugs like Me... [Published FiercePharma - Jun 12 2013]
Merck & Co., Inc. (MRK), Pfizer Inc. (PFE): Doe... [Published InsiderMonkey.com - Jun 12 2013]
UPDATE: Merck Backs Call for Independent Review... [Published ADVFN India - Jun 12 2013]
UPDATE: Merck Backs Call for Independent Review... [Published Capital.gr - Jun 12 2013]
Does This Pipeline Promise Tomorrow's Blockbust... [Published Motley Fool Discussion Boards - Jun 12 2013]

Blogs

sort by: Date \| Relevance
A Bristol-Myers And AstraZeneca Diabetes Trial ... [Published Pharmalot - 2 hours ago] In a setback to an important joint venture between Bristol-Myers Squibb (BMY) and AstraZeneca (AZN), the top-line results of a large, late-stage study of their Onglyza diabetes drug failed to show superiority in reducing cardiovascular deaths, heart ...
READER POLL: Should Diabetes Drugmakers Provide... [Published Pharmalot - Jun 17 2013] Last week, the NIH ran a workshop to examine the safety of several widely used diabetes drugs and whether a definitive link can be established to acute pancreatitis and pancreatic cancer, which were the subject of recent studies that have generated ...
New Merck R&D Chief Overhauls Operations & Cuts... [Published Pharmalot - Jun 14 2013] Two months after arriving at Merck as the new head of R&D, Roger Perlmutter is moving quickly to overhaul the operation, which is known as Merck Research Laboratories ( back story ). As part of the changes, various senior management roles have been ...
Cancer of The Pancreas: Possible Side Effect Fo... [Published Drug Injury Watch - Jun 12 2013] Diabetes Doctors And Drug Safety Watchdog Group Express More Concern Than Ever Following June 2013 BMJ Medical Journal Article (Posted by Tom Lamb at DrugInjuryWatch.com ) In mid-March 2013 we wrote this article, "Emerging Drug Safety Issue: ...
Hewlett-Packard Moves Toward Enterprise Storage... [Published Wall St. Cheat Sheet - Jun 12 2013] Hewlett-Packard Co. ( NYSE:HPQ ) Current price $25.10Following the launch of the ‘Moonshot’ server two months ago, HP has now unveiled a number of new storage solutions that will push the company farther toward the lucrative enterprise storage space, at ...

Audio/Video

sort by: Date \| Relevance
Januvia Weighs Down Merck's Sales [Published TheStreet.com - YouTube - May 01 2013]

Press Releases

sort by: Date \| Relevance
Suit filed for Pancreatic Cancer By Use of Byet... [Published PR Newswire: Health - Jun 17 2013]
Merck Welcomes Independent Review of the Safety... [Published Business Wire Health News - Jun 12 2013]
Pharmaceutical Executive Magazine's 2013 Drug "... [Published PR Newswire: General Business - Mar 26 2013]